Background-landing
Outreach
The need to raise awareness extends from the bench to the bedside. SNMMI’s Outreach Program focuses on collaborating with key provider and patient organizations to educate the medical and patient communities about the demonstrated value of nuclear medicine, molecular imaging and radionuclide therapy in providing the most effective and efficient care for patients.
The Patient Advocacy Advisory Board has now expanded to include the Susan G. Komen for the Cure, bringing the total number of participating organizations to 11. SNMMI Patient Advocacy Advisory Board members participated in a Capitol Hill Fly-In in March 2018 to advocate for a bill to reclassify diagnostic radiopharmaceuticals as drugs. SNMMI outreach working groups are collaborating with patient advocacy organizations on diverse projects, including creating and updating factsheets, creating “What to Expect” videos for patients undergoing brain scans, improving the patient-focused social media and funding/planning events. A plan is also being developed for outreach at the chapter level to engage local and regional patient groups.
Educating and engaging patients.
In the coming year, SNMMI is engaging referring physicians through a number of events to raise awareness of nuclear medicine and new radiopharmaceuticals. The society has planned two ancillary educational events on nuclear medicine for prostate cancer and neuroendocrine tumors (NETS) at the American Society of Clinical Oncology’s annual meeting, six “roadshow” events on NETS, an exhibit and presentation at the American Urological Association, and a session on PET at the American Society of Neuroradiology. In addition, SNMMI is working with industry to develop continuing medical education programs on new and existing topics and the use of industry products. SNMMI is focusing on educating providers and patients about available tests, ongoing research, and appropriate use criteria (AUC). Fact sheets on new AUC and training modules are being developed, and chapter representatives will assist with spreading the word at the local level.
Increasing referring physicians’ awareness of new radiopharmaceuticals.
SNMMI is working with the societies that collaborated on AUC development to disseminate the AUC to their members. Outreach working groups are developing training modules for referrers on novel radiopharmaceuticals. The society is holding reciprocal joint annual meeting sessions with the North American Neuroendocrine Tumor Society and the American Thyroid Association (ATA). In addition, SNMMI met with the ATA and other stakeholders at the Multilateral Conference on Differentiated Thyroid Cancer to explore development of a white paper on thyroid guidelines.
Collaboration with Medical Societies.
Signing JSNM-SNMMI memorandum of understanding in Yokohama, Japan: (left to right) Drs. Michio Senda; Nagara Tamaki; Jun Hatazawa; Ben Greenspan, SNMMI president; Satoshi Minoshima, SNMMI president-elect; Hiroshi Matsuda; and Hirofumi Fujii
Speakers at SNMMI's NET Roadshow: “Advances in Nuclear Imaging and Therapy for Neuroendocrine Tumors." (left to right) Michael Choti, MD, MBA; patient advocate Josh Mailman; Rathan M. Subramaniam, MD, PhD, MPH; and Yull Arriaga, MD.
SNMMI LogoValue Initiative logo